Array Biopharma, Inc. (ARRY) Posts Q2 Loss of $0.06, Sales Top Expectations
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.23 +0.71%
Revenue Growth %: -16.2%
Financial Fact:
Total revenue: 39.27M
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: -16.2%
Financial Fact:
Total revenue: 39.27M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q2 EPS of ($0.06), $0.06 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $21.76 million.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS sees a negative catalyst ahead for Nike: Here’s what to watch
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- Copart launches $10.50-per-share tender offer to acquire ACV
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
